BiotechTube

IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CLDN18.2-positive Gastric Adenocarcinoma

Conditions

CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus

Trial Timeline

Oct 16, 2012 → Oct 13, 2014

NCT ID
NCT01671774

About IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)

IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU) is a phase 1 stage product being developed by Astellas Pharma for CLDN18.2-positive Gastric Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01671774. Target conditions include CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01671774Phase 1Completed

Competing Products

1 competing product in CLDN18.2-positive Gastric Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85